Novo Nordisk reports 1 million Wegovy patients and 2.3 bn DKK sales in Q1 amid pricing pressure
read at Endpoints ↗EarningsNeutral
Novo Nordisk's CEO Mike Doustad said the company saw about one million patients using its obesity drug Wegovy during the first quarter.
The pill generated sales of roughly 2.3 billion Danish kroner, showing strong demand even as Eli Lilly introduced its competing drug Foundayo.
The company highlighted ongoing challenges related to drug pricing, reimbursement negotiations and market pressure as it navigates the expanding obesity market.
Analysts will watch how Novo balances growth with pricing strategies and payment models in the coming quarters.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure”
read at Endpoints ↗91 words · retrieved May 8
comments(0)
5-min edit window · permanent after that